Connect pharma enterprise sponsors with vetted AI drug discovery labs, computational biology teams, and TechBio startups. Over $3.5M in active contract funding available.
De novo Macrocyclic Peptide Design against KRAS G12D
Global Top-10 Pharma (Oncology Division) · Enterprise Pharma
Seeking machine learning partners to design high-affinity macrocyclic peptides targeting the switch-II pocket of KRAS G12D with sub-nanomolar affinity and high membrane permeability.
Predicting Off-Target Toxicity via Spatial Transcriptomics GNNs
Boston Flagship Biotech · Clinical Stage Biotech
Development of graph neural network models combining 10x Visium spatial transcriptomics with chemical fingerprints to forecast organ-specific off-target liabilities in preclinical animal cohorts.
Cryo-EM Automated Density Map Fitting with Deep Generative Models
Cambridge Structural AI Institute · Academic / Consortium
Open-source benchmark and model pipeline to fit atomic coordinates into low-resolution (3.5 - 5.0 Å) Cryo-EM single-particle reconstructions with high confidence and automated sidechain placement.
High-Throughput Virtual Screening of 10B Ultra-Large Chemical Library
Swiss Oncology Venture · Series B Biotech
Ultra-fast GPU-accelerated molecular docking and ML rescoring across the complete Enamine REAL 10-billion compound space against 3 novel epigenetic targets.
DiffDock / Uni-MolGPU Cluster OrchestrationEnamine REAL SpaceADMET Profiling
BUDGET$650,000 - $900,000
DEADLINE2026-10-30
RFP-2026-141Open
Multi-Specific Antibody Affinity Maturation using Generative Protein Models
Bay Area Immuno-Oncology Lab · Enterprise Biotech
Optimize binding affinity of a bispecific T-cell engager (BiTE) against HER2/CD3 while reducing non-specific liver clearance and viscosity at high concentration formulations.
Foundational RNA Secondary Structure Prediction with Pseudoknots
Nordic RNA Therapeutics Hub · Research Foundation
Benchmarking and novel deep learning architectures for secondary and tertiary structure prediction of synthetic circular RNAs and mRNA vaccine constructs.